Feature | Type 1 AIH | Type 2 AIH |
Characteristic autoantibodies |
|
|
Geographical variation | Worldwide | Worldwide |
Age at presentation | All ages | Usually childhood and young adulthood |
Sex (F:M) | 3:1 | 10:1 |
Clinical phenotype | Variable | Generally severe |
Histopathological features at presentation | Broad range: mild disease to cirrhosis |
|
Treatment failure | Rare | Common |
Relapse after drug withdrawal | Variable | Common |
Need for long-term maintenance | Variable | Approximately 100% |
Although immunofluorescence is the traditional method for measuring the repertoire of conventional autoantibodies in AIH, many laboratories (especially those in the USA) are increasingly using ELISA-based methods, especially for anti-LKM antibodies. In relation to anti-LKM-1 antibodies, these may be erroneously reported as detectable anit-mitochondral antibodies.
ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; anti-LC, anti-liver cytosol; anti-LKM, liver kidney microsomal antibody; anti-SLA/LP, soluble liver antigen/liver pancreas antigen.